Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775460 | 0.89 | OPRM1 (0.36) | KDM4EHDAC1HDAC8 | |
| SCHEMBL2844016 | 0.80 | MTNR1A (0.38) | — | |
| SCHEMBL4748761 | 0.78 | MAOA (0.32) | — | |
| SCHEMBL4514757 | 0.78 | OPRK1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL4521946 | 0.77 | MAOA (0.31) | ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL4504167 | 0.77 | OPRK1 (0.32) | — | |
| SCHEMBL6961084 | 0.77 | PRCP (0.39) | ALDH1A1KDM4ELMNA | |
| SCHEMBL6960867 | 0.76 | PARP1 (0.36) | ALDH1A1KDM4E | |
| SCHEMBL6969207 | 0.76 | SIRT2 (0.39) | HDAC1HDAC8 | |
| SCHEMBL6966047 | 0.76 | ESR1 (0.37) | HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102599-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2392567-B1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-1951676-B1 | N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-1994015-B1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8404896-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-6207664-B1 | USEFUL AS HYPOCHOLESTEROLEMIC AGENTS, HYPOTRIGLYCERIDEMIC AGENTS, HYPOTRIGLYCERIDEMIC AGENTS, ANTIATHEROSCLEROSIS AGENTS, ANTIFUNGAL AGENTS, ANTI-ALZHEIMER'S AGENTS OR ANTI-ACNE AGENTS | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| US-6147090-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS USED TO TREAT DISEASES WHICH ARE EXACERBATED BY LOW LEVELS OF HDL CHOLESTEROL AND/OR HIGH LEVELS OF LDL-CHOLESTEROL AND TRIGLYCERIDES, SUCH AS ATHEROSCLEROSIS AND CARDIOVASCULAR | PFIZER INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6147089-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS USED TO TREAT DISEASES WHICH ARE EXACERBATED BY LOW LEVELS OF HDL CHOLESTEROL AND/OR HIGH LEVELS OF LDL-CHOLESTEROL AND TRIGLYCERIDES, SUCH AS ATHEROSCLEROSIS AND CARDIOVASCULAR | PFIZER INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6140342-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR; USED TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN OTHER PLASMA LIPID LEVELS, SUCH AS LDL-CHOLESTEROL AND TRIGLYCERIDES | PFIZER INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0992496-A1 | Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000017165-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017166-A1 | 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017164-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0987251-A1 | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | Pfizer Products Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | HRH2 3404/4885ALDH1A1 2353/4885KDM4E 1618/4885 |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | HRH2 2707/4885ALDH1A1 2112/4885KDM4E 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.